Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 669-677

  Zhao, Dongmei ^a   Zhao, Xiuhua ^a   Zu, Yuangang ^a   Li, Jialei ^a   Zhang, Yu ^a   Jiang, Ru ^a   Zhang, Zhonghua ^a  

^a NORTHEAST FORESTRY UNIVERSITY   (China)

Author keywords

Bovine serum albumin; Folate; Nanoparticles; Paclitaxel; Target delivery

Indexed keywords

BOVINE SERUM ALBUMIN; FLUORESCEIN ISOTHIOCYANATE; FOLIC ACID; NANOPARTICLE; PACLITAXEL; ANTINEOPLASTIC AGENT; DRUG CARRIER;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; COVALENT BOND; CROSS LINKING; DRUG DETERMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; LABELING INDEX; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; PARTICLE SIZE; PROSTATE CANCER; SURFACE PROPERTY; TARGET CELL; ZETA POTENTIAL; ANIMAL; CATTLE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG STABILITY; MALE; METABOLISM; METHODOLOGY; PROSTATE TUMOR; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; TUMOR CELL LINE; ULTRASTRUCTURE;

BOVINAE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATTLE; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FOLIC ACID; HUMANS; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; PROSTATIC NEOPLASMS; SERUM ALBUMIN, BOVINE; SOLUBILITY; SURFACE PROPERTIES;

EID: 79952118190     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S12918     Document Type: Article

References (35)

1. Szebeni J, Muggia FM, Alving CR. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study. J Natl Cancer Inst. 1998;90(4):300-306.
2. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf. 2000;23(5):401-428.
3. Dosio F, Brusa P, Crosasso P, Arpicco S, Cattel L. Preparation, characterization and properties in vitro and in vivo of a paclitaxelalbumin conjugate. J Control Release. 1997;47(3):293-304.
4. Skwarczynski M, Hayashi Y, Kiso Y. Paclitaxel prodrugs: Toward smarter delivery of anticancer agents. J Med Chem. 2006;49(25): 7253-7269.
5. Marupudi NI, Han JE, Li KW, et al. Paclitaxel: A review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007; 6(5):609-621.
6. Desai N, Teieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor- based paclitaxel. Clin Cancer Res. 2006;12(4): 1317-1324.
7. Gradishar WJ, Tjulandin S, Davodson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794-7803.
8. Huh KM, Lee SC, Cho YW, Lee J, Jeong JH, Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release. 2005;101(1-3):56-68.
9. Suh H, Jeong B, Rathi R, Kim SW. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)- poly(lactide/glycolide) nanospheres. J Biomed Mater Res. 1998;42(2): 331-338.
10. Seow WY, Xue JM, Yang YY. Targeted and intracellular delivery of paclitaxel using multi-functiona l polymeric micells. Biomaterials. 2007;28(9):1730-1740.
11. Zhang Y, Tang L, Sun L, et al. A novel paclitaxel-loaded poly(e-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater. 2010;6(6): 2045-2052.
12. Temming K, Meyer DL, Zabinski R, et al. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjug Chem. 2006;17(6):1385-1394.
13. Temming K, Meyer DL, Zabinski R, et al. Improved efficacy avß3- targeted albumin conjugates by conjugation of a novel auristatin derivative. Mol Pharm. 2007;4(5):686-694.
14. Rahimnejad M, Jahanshahi M, Najafpour GD. Production of biological nanoparticles from bovine serum albumin for drug delivery. Afr J Biotechnol. 2006;5(20):1918-1923.
15. ®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17(8):1263-1268.
16. ® ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99-105.
17. Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041-1053.
18. Gruner BA, Weitman SD. The folate receptor as a potential therapeutic anticancer target. Invest New Drugs. 1999;16(3):205-219.
19. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54(5):675-693.
20. Sabharanjak S, Mayor S. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev. 2004;56(8):1099-1109.
21. Zheng Y, Song SG, Darby M, et al. Preparation and characterization of folate-poly(ethylene glycol)-grafted-trimethylchitosan for intracellular transport of protein through folate receptor-mediated endocytosis. J Biotechnol. 2009;145(1):47-53.
22. Dosio F, Arpico S, Stella B, Brusa P, Cattel L. Folate-mediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system. Int J Pharm. 2009;382(1-2):117-123.
23. Li FQ, Su H, Wang J, Liu YJ, et al. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for live targeting. Int J Pharm. 2008;349(1-2):274-282.
24. Weber C, Coester C, Keruter J, Langer K. Desolvation process and surface characterization of protein nanoparticles. Int J Pharm. 2000;194(1):91-102.
25. Zu Y, Zhang Y, Zhao X, Zhang Q, Liu Y, Jiang R. Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate conjugated bovine serum albumin (BSA) nanoparticles for tumortargeted drug delivery using response surface methodology (RSM). Int J Nanomedicine. 2009;4:321-333.
26. Lee R, Low P. Delivery of liposomes into cultured KB cells via folate receptor mediated endocytosis. J Biol Chem. 1994;269(5): 3198-3204.
27. Zhang L, Hou S, Mao S, Wei D, Song X, Lu Y. Uptake of folate- conjugated albumin nanoparticles to the SKOV3 cells. Int J Pharm. 2004;287(1-2):155-162.
28. Meziani MJ, Sun YP. Protein-conjugated nanoparticles from rapid expansion of supercritical fluid solution into aqueous solution. J Am Chem Soc. 2003;125(26):8015-8018.
29. Merodio M, Arnedo A, Renedo MJ, Irache JM. Ganciclovir-loaded albumin nanoparticles: Characterization and in vitro release properties. Eur J Pharm Sci. 2001;12(3):251-259.
30. Cho WY, Lee J, Lee SC, Huh KM, Park K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release. 2004;97(2):249-257.
31. Hattori Y, Maitani Y. Enhanced in vitro DNA transfection efficiency by novel folate-linked nanoparicles in human prostate cancer and oral cancer. J Control Release. 2004;97(1):173-183.
32. Holm J, Hansen SI, Hoier-Madsen M. High-affinity folate binding in human prostate. Biosci Rep. 1993;13(2):99-105.
33. Hattori Y, Maitani Y. Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther. 2005; 12(10):796-809.
34. Paal K, Muller J, Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem. 2001;268(7):2187-2191.
35. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26(1):57-64.